Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
115 | Publisher: QYResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Notes: Sales, means the sales volume of Non-Insulin Therapies for Diabetes Revenue, means the sales value of Non-Insulin Therapies for Diabetes This report studies sales (consumption) of Non-Insulin Therapies for Diabetes in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering GSK Eli Lilly Sumitomo Dainippon Pharma Intarcia Therapeutics Servier Jiangsu Hansoh Pharmaceutical Novo Nordisk Emisphere Uni-Bio Science Group Takeda 3SBio Merck Dong-A Pharmaceutical Luye Pharma Group Eurofarma Geropharm Alkem Labs SatRx Pfizer Jiangsu Hengrui Medicine Market Segment by States, covering California Texas New York Florida Illinois Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into Alpha-Glucosidase Inhibitors Amylin Agonists Biguanides Dipeptidyl Peptidase-4 (DPP4) Inhibitors Glinides/Meglitinides GLP-1 Analogs/GLP-1 Agonists Sodium-Glucose Cotransporter2(SGLT2)Inhibitors Sulfonylureas Thiazolidinediones Others Split by applications, this report focuses on sales, market share and growth rate of Non-Insulin Therapies for Diabetes in each application, can be divided into Hospital Pharmacy Retail Pharmacies Online Pharmacy Others
Table of Contents United States Non-Insulin Therapies for Diabetes Market Report 2017 1 Non-Insulin Therapies for Diabetes Overview 1.1 Product Overview and Scope of Non-Insulin Therapies for Diabetes 1.2 Classification of Non-Insulin Therapies for Diabetes 1.2.1 Alpha-Glucosidase Inhibitors 1.2.2 Amylin Agonists 1.2.3 Biguanides 1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors 1.2.5 Glinides/Meglitinides 1.2.6 GLP-1 Analogs/GLP-1 Agonists 1.2.7 Sodium-Glucose Cotransporter2(SGLT2)Inhibitors 1.2.8 Sulfonylureas 1.2.9 Thiazolidinediones 1.2.10 Others 1.3 Application of Non-Insulin Therapies for Diabetes 1.3.1 Hospital Pharmacy 1.3.2 Retail Pharmacies 1.3.3 Online Pharmacy 1.3.4 Others 1.4 United States Market Size Sales (Volume) and Revenue (Value) of Non-Insulin Therapies for Diabetes (2012-2022) 1.4.1 United States Non-Insulin Therapies for Diabetes Sales and Growth Rate (2012-2022) 1.4.2 United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2022) 2 United States Non-Insulin Therapies for Diabetes Competition by Manufacturers 2.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share of Key Manufacturers (2015 and 2016) 2.2 United States Non-Insulin Therapies for Diabetes Revenue and Share by Manufactures (2015 and 2016) 2.3 United States Non-Insulin Therapies for Diabetes Average Price by Manufactures (2015 and 2016) 2.4 Non-Insulin Therapies for Diabetes Market Competitive Situation and Trends 2.4.1 Non-Insulin Therapies for Diabetes Market Concentration Rate 2.4.2 Non-Insulin Therapies for Diabetes Market Share of Top 3 and Top 5 Manufacturers 2.4.3 Mergers & Acquisitions, Expansion 3 United States Non-Insulin Therapies for Diabetes Sales (Volume) and Revenue (Value) by States (2012-2017) 3.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by States (2012-2017) 3.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by States (2012-2017) 3.3 United States Non-Insulin Therapies for Diabetes Price by States (2012-2017) 4 United States Non-Insulin Therapies for Diabetes Sales (Volume) and Revenue (Value) by Type (2012-2017) 4.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Type (2012-2017) 4.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2012-2017) 4.3 United States Non-Insulin Therapies for Diabetes Price by Type (2012-2017) 4.4 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2012-2017) 5 United States Non-Insulin Therapies for Diabetes Sales (Volume) by Application (2012-2017) 5.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Application (2012-2017) 5.2 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017) 5.3 Market Drivers and Opportunities 6 United States Non-Insulin Therapies for Diabetes Manufacturers Profiles/Analysis 6.1 GSK 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.1.2.1 Alpha-Glucosidase Inhibitors 6.1.2.2 Amylin Agonists 6.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.1.4 Main Business/Business Overview 6.2 Eli Lilly 6.2.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.2.2.1 Alpha-Glucosidase Inhibitors 6.2.2.2 Amylin Agonists 6.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.2.4 Main Business/Business Overview 6.3 Sumitomo Dainippon Pharma 6.3.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.3.2.1 Alpha-Glucosidase Inhibitors 6.3.2.2 Amylin Agonists 6.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.3.4 Main Business/Business Overview 6.4 Intarcia Therapeutics 6.4.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.4.2.1 Alpha-Glucosidase Inhibitors 6.4.2.2 Amylin Agonists 6.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.4.4 Main Business/Business Overview 6.5 Servier 6.5.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.5.2.1 Alpha-Glucosidase Inhibitors 6.5.2.2 Amylin Agonists 6.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.5.4 Main Business/Business Overview 6.6 Jiangsu Hansoh Pharmaceutical 6.6.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.6.2.1 Alpha-Glucosidase Inhibitors 6.6.2.2 Amylin Agonists 6.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.6.4 Main Business/Business Overview 6.7 Novo Nordisk 6.7.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.7.2.1 Alpha-Glucosidase Inhibitors 6.7.2.2 Amylin Agonists 6.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.7.4 Main Business/Business Overview 6.8 Emisphere 6.8.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.8.2.1 Alpha-Glucosidase Inhibitors 6.8.2.2 Amylin Agonists 6.8.3 Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.8.4 Main Business/Business Overview 6.9 Uni-Bio Science Group 6.9.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.9.2.1 Alpha-Glucosidase Inhibitors 6.9.2.2 Amylin Agonists 6.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.9.4 Main Business/Business Overview 6.10 Takeda 6.10.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification 6.10.2.1 Alpha-Glucosidase Inhibitors 6.10.2.2 Amylin Agonists 6.10.3 Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) 6.10.4 Main Business/Business Overview 6.11 3SBio 6.12 Merck 6.13 Dong-A Pharmaceutical 6.14 Luye Pharma Group 6.15 Eurofarma 6.16 Geropharm 6.17 Alkem Labs 6.18 SatRx 6.19 Pfizer 6.20 Jiangsu Hengrui Medicine 7 Non-Insulin Therapies for Diabetes Manufacturing Cost Analysis 7.1 Non-Insulin Therapies for Diabetes Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Price Trend of Key Raw Materials 7.1.3 Key Suppliers of Raw Materials 7.1.4 Market Concentration Rate of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.2.1 Raw Materials 7.2.2 Labor Cost 7.2.3 Manufacturing Expenses 7.3 Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes 8 Industrial Chain, Sourcing Strategy and Downstream Buyers 8.1 Non-Insulin Therapies for Diabetes Industrial Chain Analysis 8.2 Upstream Raw Materials Sourcing 8.3 Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2015 8.4 Downstream Buyers 9 Marketing Strategy Analysis, Distributors/Traders 9.1 Marketing Channel 9.1.1 Direct Marketing 9.1.2 Indirect Marketing 9.1.3 Marketing Channel Development Trend 9.2 Market Positioning 9.2.1 Pricing Strategy 9.2.2 Brand Strategy 9.2.3 Target Client 9.3 Distributors/Traders List 10 Market Effect Factors Analysis 10.1 Technology Progress/Risk 10.1.1 Substitutes Threat 10.1.2 Technology Progress in Related Industry 10.2 Consumer Needs/Customer Preference Change 10.3 Economic/Political Environmental Change 11 United States Non-Insulin Therapies for Diabetes Market Forecast (2017-2022) 11.1 United States Non-Insulin Therapies for Diabetes Sales, Revenue Forecast (2017-2022) 11.2 United States Non-Insulin Therapies for Diabetes Sales Forecast by Type (2017-2022) 11.3 United States Non-Insulin Therapies for Diabetes Sales Forecast by Application (2017-2022) 11.4 Non-Insulin Therapies for Diabetes Price Forecast (2017-2022) 12 Research Findings and Conclusion 13 Appendix Methodology Analyst Introduction Data Source
List of Tables and Figures Figure Picture of Non-Insulin Therapies for Diabetes Table Classification of Non-Insulin Therapies for Diabetes Figure United States Sales Market Share of Non-Insulin Therapies for Diabetes by Type in 2015 Figure Alpha-Glucosidase Inhibitors Picture Figure Amylin Agonists Picture Figure Biguanides Picture Figure Dipeptidyl Peptidase-4 (DPP4) Inhibitors Picture Figure Glinides/Meglitinides Picture Figure GLP-1 Analogs/GLP-1 Agonists Picture Figure Sodium-Glucose Cotransporter2(SGLT2)Inhibitors Picture Figure Sulfonylureas Picture Figure Thiazolidinediones Picture Figure Others Picture Table Application of Non-Insulin Therapies for Diabetes Figure United States Sales Market Share of Non-Insulin Therapies for Diabetes by Application in 2015 Figure Hospital Pharmacy Examples Figure Retail Pharmacies Examples Figure Online Pharmacy Examples Figure Others Examples Figure United States Non-Insulin Therapies for Diabetes Sales and Growth Rate (2012-2022) Figure United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2022) Table United States Non-Insulin Therapies for Diabetes Sales of Key Manufacturers (2015 and 2016) Table United States Non-Insulin Therapies for Diabetes Sales Share by Manufacturers (2015 and 2016) Figure 2015 Non-Insulin Therapies for Diabetes Sales Share by Manufacturers Figure 2016 Non-Insulin Therapies for Diabetes Sales Share by Manufacturers Table United States Non-Insulin Therapies for Diabetes Revenue by Manufacturers (2015 and 2016) Table United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2015 and 2016) Table 2015 United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers Table 2016 United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers Table United States Market Non-Insulin Therapies for Diabetes Average Price of Key Manufacturers (2015 and 2016) Figure United States Market Non-Insulin Therapies for Diabetes Average Price of Key Manufacturers in 2015 Figure Non-Insulin Therapies for Diabetes Market Share of Top 3 Manufacturers Figure Non-Insulin Therapies for Diabetes Market Share of Top 5 Manufacturers Table United States Non-Insulin Therapies for Diabetes Sales by States (2012-2017) Table United States Non-Insulin Therapies for Diabetes Sales Share by States (2012-2017) Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by States in 2015 Table United States Non-Insulin Therapies for Diabetes Revenue and Market Share by States (2012-2017) Table United States Non-Insulin Therapies for Diabetes Revenue Share by States (2012-2017) Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by States (2012-2017) Table United States Non-Insulin Therapies for Diabetes Price by States (2012-2017) Table United States Non-Insulin Therapies for Diabetes Sales by Type (2012-2017) Table United States Non-Insulin Therapies for Diabetes Sales Share by Type (2012-2017) Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Type in 2015 Table United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2012-2017) Table United States Non-Insulin Therapies for Diabetes Revenue Share by Type (2012-2017) Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by Type (2012-2017) Table United States Non-Insulin Therapies for Diabetes Price by Type (2012-2017) Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2012-2017) Table United States Non-Insulin Therapies for Diabetes Sales by Application (2012-2017) Table United States Non-Insulin Therapies for Diabetes Sales Market Share by Application (2012-2017) Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Application in 2015 Table United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017) Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017) Table GSK Basic Information List Table GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Figure GSK Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Eli Lilly Basic Information List Table Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Eli Lilly Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Sumitomo Dainippon Pharma Basic Information List Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Intarcia Therapeutics Basic Information List Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Servier Basic Information List Table Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Servier Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Jiangsu Hansoh Pharmaceutical Basic Information List Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Novo Nordisk Basic Information List Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Emisphere Basic Information List Table Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Emisphere Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Uni-Bio Science Group Basic Information List Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table Takeda Basic Information List Table Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017) Table Takeda Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017) Table 3SBio Basic Information List Table Merck Basic Information List Table Dong-A Pharmaceutical Basic Information List Table Luye Pharma Group Basic Information List Table Eurofarma Basic Information List Table Geropharm Basic Information List Table Alkem Labs Basic Information List Table SatRx Basic Information List Table Pfizer Basic Information List Table Jiangsu Hengrui Medicine Basic Information List Table Production Base and Market Concentration Rate of Raw Material Figure Price Trend of Key Raw Materials Table Key Suppliers of Raw Materials Figure Manufacturing Cost Structure of Non-Insulin Therapies for Diabetes Figure Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes Figure Non-Insulin Therapies for Diabetes Industrial Chain Analysis Table Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2015 Table Major Buyers of Non-Insulin Therapies for Diabetes Table Distributors/Traders List Figure United States Non-Insulin Therapies for Diabetes Production and Growth Rate Forecast (2017-2022) Figure United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate Forecast (2017-2022) Table United States Non-Insulin Therapies for Diabetes Production Forecast by Type (2017-2022) Table United States Non-Insulin Therapies for Diabetes Consumption Forecast by Application (2017-2022) Table United States Non-Insulin Therapies for Diabetes Sales Forecast by States (2017-2022) Table United States Non-Insulin Therapies for Diabetes Sales Share Forecast by States (2017-2022)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.